Equities Analysts Offer Predictions for Glaukos Q2 Earnings

Glaukos Co. (NYSE:GKOS - Free Report) - Analysts at Zacks Research cut their Q2 2025 EPS estimates for Glaukos in a note issued to investors on Wednesday, May 21st. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings per share of ($0.28) for the quarter, down from their previous forecast of ($0.27). The consensus estimate for Glaukos' current full-year earnings is ($1.08) per share. Zacks Research also issued estimates for Glaukos' Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.96) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at $0.03 EPS, FY2026 earnings at $0.05 EPS, Q1 2027 earnings at $0.10 EPS and FY2027 earnings at $1.01 EPS.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The company had revenue of $106.66 million for the quarter, compared to the consensus estimate of $102.78 million. During the same quarter in the prior year, the company earned ($0.70) EPS. The firm's quarterly revenue was up 24.6% on a year-over-year basis.

GKOS has been the topic of a number of other reports. Mizuho dropped their price target on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 16th. Stephens dropped their target price on Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Truist Financial reiterated a "buy" rating and set a $135.00 price target (down from $140.00) on shares of Glaukos in a report on Thursday, May 1st. Morgan Stanley dropped their price objective on Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Finally, Stifel Nicolaus cut their price objective on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a research report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $134.67.

Glaukos Stock Down 2.0%

GKOS stock traded down $1.93 during midday trading on Friday, reaching $95.04. The company had a trading volume of 189,327 shares, compared to its average volume of 697,708. The company has a 50 day moving average of $93.25 and a two-hundred day moving average of $124.03. The company has a market capitalization of $5.43 billion, a P/E ratio of -33.12 and a beta of 0.83. Glaukos has a 1 year low of $77.10 and a 1 year high of $163.71. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19.

Insiders Place Their Bets

In other news, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. The trade was a 2.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.40% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of GKOS. Barclays PLC increased its stake in shares of Glaukos by 394.4% in the third quarter. Barclays PLC now owns 89,699 shares of the medical instruments supplier's stock worth $11,686,000 after purchasing an additional 71,556 shares during the period. SG Americas Securities LLC grew its holdings in Glaukos by 42.1% in the 4th quarter. SG Americas Securities LLC now owns 3,641 shares of the medical instruments supplier's stock valued at $546,000 after buying an additional 1,078 shares during the last quarter. Avior Wealth Management LLC bought a new position in Glaukos in the 4th quarter worth approximately $390,000. Zweig DiMenna Associates LLC acquired a new position in shares of Glaukos during the fourth quarter worth approximately $8,796,000. Finally, KBC Group NV boosted its position in shares of Glaukos by 67.3% in the fourth quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier's stock valued at $362,000 after acquiring an additional 972 shares during the period. Institutional investors own 99.04% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.